Agios Pharmaceuticals (NASDAQ:AGIO) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO) from a strong sell rating to a hold rating in a research note released on Tuesday,Zacks.com reports.

Other analysts also recently issued reports about the company. HC Wainwright restated a “buy” rating and set a $56.00 price objective on shares of Agios Pharmaceuticals in a research report on Thursday, September 4th. Weiss Ratings restated a “hold (c-)” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, October 8th. Bank of America dropped their price objective on Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating for the company in a research report on Tuesday, July 22nd. Finally, Scotiabank dropped their price objective on Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a research report on Monday, July 28th. Five equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.25.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ:AGIO opened at $40.51 on Tuesday. The company’s 50 day simple moving average is $39.67 and its 200 day simple moving average is $36.09. The stock has a market capitalization of $2.36 billion, a price-to-earnings ratio of -5.79 and a beta of 0.89. Agios Pharmaceuticals has a 1 year low of $23.42 and a 1 year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.15. The business had revenue of $12.90 million for the quarter, compared to analysts’ expectations of $10.49 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The firm’s quarterly revenue was up 43.3% compared to the same quarter last year. During the same period last year, the firm posted $16.22 earnings per share. As a group, analysts anticipate that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Insider Activity at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 3,651 shares of the firm’s stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $36.77, for a total value of $134,247.27. Following the sale, the chief financial officer owned 33,870 shares in the company, valued at $1,245,399.90. This trade represents a 9.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Sarah Gheuens sold 3,302 shares of the firm’s stock in a transaction on Monday, October 27th. The shares were sold at an average price of $43.92, for a total transaction of $145,023.84. Following the transaction, the insider directly owned 61,727 shares of the company’s stock, valued at $2,711,049.84. The trade was a 5.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 26,984 shares of company stock worth $1,017,811. Corporate insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several large investors have recently modified their holdings of AGIO. CWM LLC raised its stake in shares of Agios Pharmaceuticals by 150.2% during the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 996 shares during the last quarter. Victory Capital Management Inc. raised its stake in shares of Agios Pharmaceuticals by 28.8% during the first quarter. Victory Capital Management Inc. now owns 8,784 shares of the biopharmaceutical company’s stock valued at $257,000 after acquiring an additional 1,964 shares during the last quarter. GW&K Investment Management LLC raised its stake in shares of Agios Pharmaceuticals by 19.6% during the first quarter. GW&K Investment Management LLC now owns 817,526 shares of the biopharmaceutical company’s stock valued at $23,954,000 after acquiring an additional 134,063 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Agios Pharmaceuticals during the first quarter valued at $1,601,000. Finally, TD Asset Management Inc raised its stake in shares of Agios Pharmaceuticals by 7.5% during the first quarter. TD Asset Management Inc now owns 178,072 shares of the biopharmaceutical company’s stock valued at $5,218,000 after acquiring an additional 12,400 shares during the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.